Regeneron Pharmaceuticals, Inc. (REGN) — Form 8-K: Current report

Regeneron Pharmaceuticals, Inc. entered into an amendment to its license and collaboration agreement with Sanofi to co-develop four new antibodies. Under the agreement, Sanofi will pay Regeneron $1.0 billion upfront and up to $7.0 billion in potential milestones, and profits will be shared equally. Additionally, Regeneron expects a pre-tax acquired research and development charge of approximately $22 million for the third quarter of 2026, and settled a lawsuit with Sanofi.